1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Tricida Inc (TCDA)
  7. Quote


Tricida Stock Price

-0.08 (-1.78%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 157,665
Bid Price 3.00
Ask Price 4.42
News -
Day High 4.52


52 Week Range


Day Low 4.3201
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Tricida Inc TCDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -1.78% 4.41 00:00:02
Open Price Low Price High Price Close Price Prev Close
4.52 4.3201 4.52 4.41 4.49
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,473 157,665 $ 4.39 $ 691,610 - 3.55 - 9.08
Last Trade Time Type Quantity Stock Price Currency
16:00:10 97 $ 4.41 USD


Draw Mode:

Tricida Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 222.39M 50.43M 29.12M $ - $ - -5.29 -1.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -51.78k 2.60%

more financials information »

Tricida News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TCDA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.754.854.32014.5568,258-0.34-7.16%
1 Month4.464.854.104.45183,526-0.05-1.12%
3 Months4.034.853.554.18189,9760.389.43%
6 Months4.765.413.554.45279,553-0.35-7.35%
1 Year8.819.083.555.77637,021-4.40-49.94%
3 Years30.1644.303.5516.25454,327-25.75-85.38%
5 Years25.0044.303.5516.91432,063-20.59-82.36%

Tricida Description

Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.